Karo Pharma acquires Trimb

25 June 2019 | 4:27 pm
Business deal
The company has acquired all the shares of Trimb Holding AB from Avista Capital Partners and other shareholders for MSEK 3,400. The transaction is expected to contribute positively to Karo Pharma’s market position and create a strong platform for Karo Pharma’s continued growth. The combined company had annual sales of approximately MSEK 2,640 for 2018. […]

First patient enrolled in PCI Biotech study

24 June 2019 | 1:28 pm
Per Walday
The company has announced that the first patient has been enrolled in the fimaChem RELEASE study with registration intent in inoperable bile duct cancer patients. The pivotal RELEASE study has the potential of accelerated/conditional marketing approval as a first-line treatment given the rare disease status and high unmet medical need in this patient population, which […]

13 Scandinavian start-ups granted EIT Health Headstart funding

24 June 2019 | 1:26 pm
The start-ups were selected from around 50 applicants and the funding will allow the start-ups to take steps towards market launch and commercialization. The 13 start-ups represent solutions in medtech, digital health and diagostics. They span areas from cancer diagnostics and multiparametric tests, surgical equipment, medical technologies related to Alzheimers, cancer treatment software, dental implants, machine […]

Novo Nordisk’s Esperoct approved in the EU

24 June 2019 | 11:47 am
Mads Krogsgaard Thomsen
The European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents and adults with haemophilia A. The authorisation covers all 28 European Union member states. About Esperoct Esperoct is the brand name for turoctocog alfa pegol, N8-GP. Esperoct is indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures […]

Alligator Bioscience submits clinical trial application

20 June 2019 | 6:50 am
Alligator Bioscience submits clinical trial application
The company has submitted clinical trial authorization (CTA) application to initiate a Phase I study of its fully owned 4-1BB antibody ATOR-1017 for the treatment of metastasizing cancer. ATOR-1017 is an immunostimulatory IgG4 antibody that activates tumor-specific T cells and NK cells through the costimulatory receptor 4-1BB. T cells and NK cells have the capacity […]

Idogen establishes a new method for the preparation of their tolerogenic cell therapy

19 June 2019 | 6:57 am
In January 2019 an evaluation of a number of new potential methods in an improved analysis model was initiated, which makes it possible to assess the tolerogenic effect on human immune cells in the laboratory with improved precision, states the company. Idogen announced in January 2019 that analyses performed in a scientifically improved evaluation model showed that the […]

Orion – one of the most popular employers in Finland

19 June 2019 | 5:16 am
Orion production
In Universum’s student survey on ideal workplaces Orion was ranked third by natural science students. The Natural Resources Institute Finland was the student’s number one choice and the Finnish Environment Institute their second. “Third place is a great achievement and makes us very proud and happy. This is also an award for our systematic work […]

Sara Mangsbo named Entrepreneur of the year

18 June 2019 | 12:33 pm
Sara Mangsbo
Researcher and entrepreneur Sara Mangsbo has won the first prize for Entrepreneur of the Year in this year’s Super Talent competition. The Swedish magazine, Veckans affärer, awards Sweden’s 101 Super Talents each year. By highlighting the individual drive, talent, knowledge and skills of young people, the publication strengthens and promotes them as the next generation […]

New Project Manager at LIDDS

18 June 2019 | 12:14 pm
Erwin Brenndörfer
Erwin Brenndörfer has joined LIDDS as Project Manager Translational Medicine. Erwin will be responsible for managing LIDDS portfolio of pre-clinical studies as well as continuing the development of the NanoZolid technology and identifying new drugs that can be combined with NanoZolid. An Assistant Professor of Infectious Diseases Erwin Brenndörfer has extensive experience in managing pre-clinical […]

New clinical data from BioInvent

18 June 2019 | 12:06 pm
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with rituximab, currently being conducting in the UK and the US/EU respectively. In the UK trial, 10 patients have received single agent therapy with up to […]